Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Portfolio Pulse from
Lucid Diagnostics' study on EsoGuard, a non-invasive esophageal precancer test, has been accepted for publication. The study shows that EsoGuard significantly increases the positive yield of invasive endoscopy for detecting Barrett's Esophagus.
March 18, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics' EsoGuard study accepted for publication, demonstrating its effectiveness in increasing diagnostic yield for Barrett's Esophagus. This could enhance the product's credibility and adoption.
The acceptance of the study in a peer-reviewed journal enhances the credibility of Lucid's EsoGuard test. This could lead to increased adoption and sales, positively impacting Lucid's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Lucid Diagnostics, a subsidiary of PAVmed, has its EsoGuard study published, potentially benefiting PAVmed through increased product credibility and sales.
As Lucid Diagnostics is a subsidiary of PAVmed, the positive news regarding EsoGuard could indirectly benefit PAVmed by enhancing its subsidiary's market position and sales.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 70